ArticleJournal of experimental & clinical cancer research : CR2024

Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

Kewen He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.